Jonathan W. Friedberg

Also affiliated with University of Rochester

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

2.1Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

American Journal of Hematology(2024)10.1002/ajh.27202

Top 10%

2.1DataRank

Top 10%24 citations

Matthew J. Maurer, Brian K. Link, Andrew L. Feldman, Thomas M. Habermann, David L. Jaye +38 more

Papers

Driven by 37 papers — median percentile 90. Top paper: “Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma”.

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

Journal of Clinical Oncology(2020)10.1200/jco.20.00303

N/A

5.0DataRank · unranked

152 citations

Kieron Dunleavy, Jeremy S. Abramson, Bayard L. Powell, Brian K. Link, Prapti A. Patel +19 more

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Blood(2020)10.1182/blood.2019003277

N/A

3.7DataRank · unranked

95 citations

Mei‐Yin C. Polley, Michael V. Knopp, Nathan C. Hall, Lale Kostakoglu, Jun Zhang +14 more

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

New England Journal of Medicine(2024)10.1056/nejmoa2405888

N/A

3.4DataRank · unranked

211 citations

Michael LeBlanc, Sharon M. Castellino, Hongli Li, Sarah C. Rutherford, Andrew M. Evens +42 more

Safety and efficacy of navitoclax, a BCL-2 and BCL-X L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study

Leukemia & lymphoma/Leukemia and lymphoma(2020)10.1080/10428194.2020.1845332

N/A

2.2DataRank · unranked

94 citations

John P. Leonard, Jonathan W. Friedberg, Jasmine Zain, Kieron Dunleavy, Rod Humerickhouse +4 more

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

American Journal of Hematology(2024)10.1002/ajh.27202

Top 10%

2.1DataRank

Top 10%24 citations

Matthew J. Maurer, Brian K. Link, Andrew L. Feldman, Thomas M. Habermann, David L. Jaye +38 more

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

New England Journal of Medicine(2017)10.1056/nejmoa1707447

N/A

1.3DataRank · unranked

5812 citations

Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson +41 more

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Blood(2022)10.1182/blood.2022015851

N/A

1.1DataRank · unranked

1538 citations

Elaine S. Jaffe, James R. Cook, Leticia Quintanilla‐Martínez, Steven H. Swerdlow, Kenneth C. Anderson +68 more

SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – Aiming to improve therapy, outcomes, and validate a prospective frailty tool

Journal of Geriatric Oncology(2021)10.1016/j.jgo.2021.10.003

N/A

0.736DataRank · unranked

24 citations

Hongli Li, Anne Beaven, Paolo F. Caimi, Leandro Cerchietti, Ash A. Alizadeh +9 more

Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101

Blood Advances(2024)10.1182/bloodadvances.2023011657

N/A

0.691DataRank · unranked

26 citations

Sharmila Giri, Amy S. Ruppert, Susan M. Geyer, Scott E. Smith, Nimish Mohile +11 more

Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial

EClinicalMedicine(2024)10.1016/j.eclinm.2024.102959

N/A

0.465DataRank · unranked

9 citations

Michael T. Brady, Myla Strawderman, Brad S. Kahl, Izidore S. Lossos, Jonathon B. Cohen +13 more

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826

Hematological Oncology(2023)10.1002/hon.3163_5

N/A

0.464DataRank · unranked

21 citations

Michael LeBlanc, Sharon M. Castellino, Huilin Li, Sarah C. Rutherford, Andrew M. Evens +41 more

ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7503

N/A

0.449DataRank · unranked

19 citations

Opeyemi A. Jegede, Peter Martin, Brian G. Till, Samir Parekh, David T. Yang +15 more

Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy

Journal of Geriatric Oncology(2021)10.1016/j.jgo.2021.07.003

N/A

0.425DataRank · unranked

16 citations

Jason Nelson, Angie Mae Rodday, Andrew M. Evens, Jonathan W. Friedberg, Tanya M. Wildes +2 more

Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis

Cancer Medicine(2023)10.1002/cam4.5628

N/A

0.320DataRank · unranked

5 citations

Levi Pederson, Michael V. Knopp, David Poon, Jun Zhang, Brad S. Kahl +10 more

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Blood Cancer Journal(2025)10.1038/s41408-025-01329-2

N/A

0.282DataRank · unranked

5 citations

Barbara Pro, Tim Illidge, Steven M. Horwitz, Lorenz Truemper, Swaminathan P. Iyer +22 more

Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps7593

N/A

0.241DataRank · unranked

4 citations

Susan M. Geyer, Stefan K. Barta, Jennifer E. Amengual, Travis Dockter, Chadwick Wright +8 more

Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8038

N/A

0.104DataRank · unranked

1 citations

Jun Yin, Levi Pederson, Betsy LaPlant, Mazyar Shadman, Hongli Li +15 more

Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial

Haematologica(2025)10.3324/haematol.2025.288057

N/A

0.104DataRank · unranked

1 citations

Hongli Li, Mazyar Shadman, Lisa M. Rimsza, Ahmad S. Zebari, Sonali M. Smith +5 more

29 | A COMPARATIVE ANALYSIS OF HISTOLOGIC TRANSFORMATION OF FOLLICULAR LYMPHOMA AT DIAGNOSIS (COMPOSITE LYMPHOMA) AND SEQUENTIALLY TRANSFORMED FOLLICULAR LYMPHOMA

Hematological Oncology(2025)10.1002/hon.70093_29

N/A

0DataRank · unranked

0 citations

Melissa C. Larson, Jonathan Day, Urshila Durani, Mazie Tsang, Dai Chihara +22 more

233 | S1608: RANDOMIZED PHASE II TRIAL COMPARING LENALIDOMIDE/OBINUTUZUMAB AND UMBRALISIB/OBINUTUZUMAB WITH CHEMOIMMUNOTHERAPY IN EARLY PROGRESSING FOLLICULAR LYMPHOMA (POD24)

Hematological Oncology(2025)10.1002/hon.70094_233

N/A

0DataRank · unranked

0 citations

H. Li, Heiko Schöder, Alex F. Herrera, Richard Burack, Brian K. Link +10 more

An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps8067

N/A

0DataRank · unranked

8 citations

Michael LeBlanc, Alex F. Herrera, Susan K. Parsons, Angela Punnett, David Hodgson +8 more

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.03.001

N/A

0DataRank · unranked

16 citations

Mehdi Hamadani, Ambuj Kumar, Peter Dreger, Jonathan W. Friedberg, Martin Dreyling +29 more

Therapy for patients with POD24 follicular lymphoma: Treatment patterns and outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.7573

N/A

0DataRank · unranked

1 citations

Melissa C. Larson, Jonathan R Day, Thomas M. Habermann, Izidore S. Lossos, Yucai Wang +15 more

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma

Blood Advances(2023)10.1182/bloodadvances.2022009467

N/A

0DataRank · unranked

14 citations

Hongli Li, Diana G. Adlowitz, Janice M. Spence, Lisa M. Rimsza, Mazyar Shadman +7 more

A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016

Hematological Oncology(2023)10.1002/hon.3163_79

N/A

0DataRank · unranked

2 citations

H. Li, Lisa M. Rimsza, John P. Leonard, Mark Kaminski, Catherine Spier +6 more

S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL

Hematological Oncology(2023)10.1002/hon.3166_ot22

N/A

0DataRank · unranked

1 citations

Patrick M. Reagan, H. Li, Hayder Saeed, Riha Vaidya, Joseph M. Unger +5 more

PHASE II/III STUDY OF R‐MINICHOP ± ORAL AZACITIDINE IN PARTICIPANTS AGE 75 YEARS OR OLDER WITH DIFFUSE LARGE B CELL AND RELATED LYMPHOMAS

Hematological Oncology(2023)10.1002/hon.3166_ot27

N/A

0DataRank · unranked

0 citations

H. Li, Anne Beaven, Paolo F. Caimi, Leandro Cerchietti, Rebecca L. Olin +9 more

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

Blood Advances(2023)10.1182/bloodadvances.2023010223

N/A

0DataRank · unranked

0 citations

Kieron Dunleavy, Jeremy S. Abramson, Brian K. Link, Bayard L. Powell, Christopher Melani +10 more

Understanding treatment decisions for Hodgkin lymphoma: a qualitative study

Leukemia & lymphoma/Leukemia and lymphoma(2023)10.1080/10428194.2023.2256913

N/A

0DataRank · unranked

0 citations

Laurie Pearson, John B. Wong, Jonathan W. Friedberg, Susan K. Parsons, Amy LeClair +1 more

Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma

JACC CardioOncology(2024)10.1016/j.jaccao.2024.02.003

N/A

0DataRank · unranked

14 citations

Jason Nelson, Benjamin Sweigart, Angie Mae Rodday, Anita J. Kumar, Marvin A. Konstam +8 more

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Blood(2024)10.1182/blood.2024025681

N/A

0DataRank · unranked

5 citations

Matthew J. Maurer, Thomas M. Habermann, Richard Burack, Jennifer R. Chapman, Jonathon B. Cohen +18 more

21 | PROGNOSTIC VALUE OF CIRCULATING TUMOR DNA IN PATIENTS WITH ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA TREATED ON SWOG S1826

Hematological Oncology(2025)10.1002/hon.70093_21

N/A

0DataRank · unranked

4 citations

Marcin Kaszkowiak, Michael LeBlanc, Chip Stewart, Alex F. Herrera, J Castillo +18 more

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201

Leukemia & lymphoma/Leukemia and lymphoma(2025)10.1080/10428194.2025.2525982

N/A

0DataRank · unranked

2 citations

Olivia Bobek, Eric D. Hsi, Timothy S. Fenske, Patrick J. Stiff, Brian T. Hill +12 more

20 | IMPACT OF EBV STATUS AND HISTOLOGY ON OUTCOMES WITH NIVOLUMAB‐AVD VERSUS Bv‐AVD IN PATIENTS ENROLLED ON SWOG S1826

Hematological Oncology(2025)10.1002/hon.70093_20

N/A

0DataRank · unranked

1 citations

H. Li, Alex F. Herrera, Anamarija M. Perry, Alexandra E. Kovach, Kelly Davison +13 more

127 | HEALTH‐RELATED QUALITY OF LIFE (HRQoL) ENDPOINTS OF THE PHASE III INTERGROUP S1826 ADVANCED‐STAGE, CLASSIC HODGKIN LYMPHOMA (cHL) TRIAL

Hematological Oncology(2025)10.1002/hon.70093_127

N/A

0DataRank · unranked

1 citations

H. Li, Alex F. Herrera, Kelly Davison, Sharon M. Castellino, Hildy Dillon +11 more

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

Journal of Clinical Oncology(2025)10.1200/jco-25-00892

N/A

0DataRank · unranked

1 citations

Vít Procházka, Tarec Christoffer El‐Galaly, Christopher R. Flowers, Diego Villa, Emmanuel Bachy +43 more

81 | REPRESSION OF miR‐29 VIA MYC LEADS TO INCREASED CD40 SIGNALING IN TRANSFORMED FOLLICULAR LYMPHOMA (FL) AND UNFAVOURABLE PROGNOSIS IN FL

Hematological Oncology(2025)10.1002/hon.70093_81

N/A

0DataRank · unranked

0 citations

Katerina Musilova Litzmanova, Filip Kledus, Miroslav Boudný, Eva Hoferková, Sheena Sharma +28 more

Jonathan W. Friedberg

Indexed papers

Top data-sharing exemplar

Papers